For the Inventor, By the Inventor

Enter assignee name

Calgary, Canada

Stem Cell Therapeutics Inc.

USPTO Granted Patents = 22

% Expired Patents = 90.9

CIPO Patents = 1

EPO Patents = 3

Forward Citations = 171

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

Samuel Weiss (19 out of 37 patents)

Christopher Gregg (9 out of 9 patents)

Tetsuro Shingo (6 out of 6 patents)

4. Emeka Enwere (3 out of 3 patents)

5. Linda Andersen (3 out of 3 patents)

6. Joseph Tucker (3 out of 3 patents)

7. Andrew K Chojnacki (2 out of 2 patents)

8. Bradley G Thompson (2 out of 151 patents)

9. Allen Davidoff (1 out of 6 patents)

10. Shigeki Ohta (1 out of 2 patents)

11. Peter M Wong (1 out of 1 patent)

12. Siu-Wah Chung (1 out of 1 patent)

13. Xiaodong Han (1 out of 1 patent)

14. Christopher Gregg (0 patent)

15. Christopher Gregg (0 patent)

22 patents: Sort by Forward Citations

1. 8470777 - Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin (2013-06-25),

2. 8435949 - Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis (2013-05-07),

3. 8343920 - Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds (2013-01-01),

4. 8333974 - Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents (2012-12-18),

5. 8222212 - Prolactin induced increase in neural stem cell numbers (2012-07-17),

6. 8217002 - Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis (2012-07-10),

7. 8143220 - Dosing regimens for neural stem cell proliferating agents and differentiating agents for the treatment of neurological disorders (2012-03-27),

8. 7994131 - Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds (2011-08-09),

9. 7964563 - Oligodendrocyte precursor cell proliferation regulated by prolactin (2011-06-21),

10. 7943376 - Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells (2011-05-17),

11. 7884072 - Prolactin induced increase in neural stem cell numbers (2011-02-08),

12. 7846898 - Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis (2010-12-07),

13. 7704737 - Oligodendrocyte production from multipotent neural stem cells (2010-04-27),

14. 7629169 - Methods for the production of platelet-derived growth factor-responsive neural precursor cells (2009-12-08),

15. 7604993 - Combined regulation of neural cell production (2009-10-20),

Stem Cell Therapeutics Inc. is a biotechnology company focused on developing and commercializing innovative therapies using stem cells. With a team of dedicated scientists and researchers, the company aims to bring novel treatments for various diseases and medical conditions. Their cutting-edge stem cell technology and proprietary methods have the potential to revolutionize the field of regenerative medicine. To learn more about Stem Cell Therapeutics Inc. and their groundbreaking work, please visit their official website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Stem Cell Therapeutics Inc.

22 Patents

#48 in Calgary

#651 in Canada

#28,704 in the World

Calgary, Canada

Stem Cell Therapeutics Inc.

Forward Citations = 171

13 inventors:

Samuel Weiss (19 out of 37 patents)

Christopher Gregg (9 out of 9 patents)

Tetsuro Shingo (6 out of 6 patents)

4. Emeka Enwere (3 out of 3 patents)

5. Linda Andersen (3 out of 3 patents)

Please report any incorrect information to [email protected]

Loading…